Madrigal Pharma (MDGL) Tops Q4 EPS by $1.77, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at H.C. Wainwright
February 27, 2025 6:05 AM ESTH.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $400.00) while maintaining a Buy rating.
The analyst comments "We upgrade STLD to Peer Perform from Underperform, using updated steel price forecasts on Trump's pledged 25%... More
TD Cowen Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL), PT $390
February 26, 2025 3:55 PM ESTTD Cowen analyst Ritu Baral reiterated a Buy rating and $390.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)
The analyst comments "4Q/FY24 Rezdiffra revs were $103M/$180M, at the top of the preannouncement range. As of YE24, 11.8K+ pts were on Tx.... More
Madrigal Pharmaceuticals (MDGL) PT Raised to $469 at Citi
February 26, 2025 3:52 PM ESTCiti analyst David Lebowitz raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $469.00 (from $378.00) while maintaining a Buy rating.
The analyst comments "Madrigal reported 4Q24 financial results, exceeding sales expectations for Rezdiffra for the third consecutive quarter since its launch... More
